Pharmanovia Collaborates with Radius Health to Commercialize Abaloparatide for Osteoporosis Treatment
Shots:
- Pharmanovia has signed an exclusive in-licensing agreement with Radius Health for abaloparatide (US brand name: Tymlos) to treat osteoporosis, expanding its osteoporosis franchise
- Pharmanovia will handle clinical, regulatory & commercial responsibilities across APAC region (China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau & Philippines), while Radius will get an upfront, regulatory & commercial milestones as well as net-sales-based tiered royalties
- Abaloparatide is a human PTH hormone related peptide analogue approved for postmenopausal women & men with osteoporosis at high fracture risk or those intolerant to other therapies, helping increase bone density
Ref: Pharmanovia | Image: Pharmanovia & Radius
Related News:- Pharmanovia Collaborates with Lindis Biotech to Commercialize Catumaxomab for Treating Malignant Ascites
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
